Compare Innovative Industrial Properties Inc (IIPR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs BIO-TECHNE Corp — how do they compare? Innovative Industrial Properties Inc trades at $51.55 (market cap $1.41B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 8.1× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays the higher dividend (14.84%). Which is the better fit depends on your goals — on Pluang, investors hold Innovative Industrial Properties Inc for 86 Days and BIO-TECHNE Corp for 63 Days on average.
| IIPR | TECH | |
|---|---|---|
Market Cap | $1.41B | $11.37B |
Volume | 483,175 | 3,153,511 |
Sector | Real Estate | Health |
52-Week High | $64.67 | $72.61 |
52-Week Low | $44.58 | $43.31 |
Typical Hold Time | 86 Days | 63 Days |
Enterprise Value | $1.95B | $11.40B |
Dividend Yield | 14.84% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IIPR trades at $51.23, up 1.93% on the day, with a bearish technical signal despite oversold RSI readings. The stock shows mixed earnings, beating in Q2 but missing in Q1, with revenue declining to $266 million in 2025. Recent news highlights a $245 million mezzanine loan commitment, while the consensus price target of $84.67 implies significant upside from current levels.
The outlook is cautious due to declining revenue and a bearish technical trend, but high dividend yield and low valuation metrics offer potential value. Key risks include tenant defaults and sector volatility, while analyst sentiment is mixed with a hold-heavy consensus.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
